Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

Market Cap	26.35B
Revenue (ttm)	742.28M
Net Income (ttm)	-133.34M
Shares Out	264.71M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,530,228
Average Volume	2,020,928
Open	99.44
Previous Close	99.67
Day's Range	98.95 - 101.77
52-Week Range	58.00 - 134.17
Beta	0.20
RSI	42.86
Earnings Date	Mar 28, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydroch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 910
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688266

Financial Performance

In 2024, SHA:688266's revenue was 532.95 million, an increase of 37.91% compared to the previous year's 386.44 million. Losses were -137.83 million, -50.52% less than in 2023.